Financial insights of BIO-B

MyFinsight

For the quarter ending 2026-03-31, BIO-B made $592,100K in revenue. -$527,100K in net income. Net profit margin of -89.02%.

Income Statement	2026-03-31	2025-12-31	2025-09-30
Net sales	592,100	494,600*	653,000
Cost of goods sold	282,700	314,500*	309,600
Gross profit	309,400	180,100*	343,400
Selling, general and administrative expense	212,400	223,900*	206,800
Research and development expense	62,900	61,700*	71,300
Impairment of purchased intangibles and related items, net	-	43,200*	-
Segment profit (gain)	34,100	-148,700*	65,300
Interest expense	12,300	12,100*	12,300
Foreign exchange (losss) gaines, net	2,400	-2,100*	2,900
(gains) losses from change in fair market value of equity securities and loan receivable	-	2,386,300*	-
Marketable securities, unrealized (gain) loss	-738,200	-	-495,300
Other nonoperating income (expense)	24,200	65,400*	8,300
Income (loss) from continuing operations before income taxes, noncontrolling interest	-689,800	2,288,800*	-431,100
(provision) benefit for income taxes	-162,700	503,200*	-89,200
Net income attributable to bio-rad	-527,100	1,785,600	-341,900

Basic EPS	-19.55	64.689	-12.7
Diluted EPS	-19.55	64.604	-12.7
Basic Average Shares	26,958,000	27,603,000	26,923,000
Diluted Average Shares	26,958,000	27,639,000	26,923,000

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.